Patient diagnostic evaluation data (n = 28)
| Characteristic | No. of patients (%) |
|---|---|
| Endoscopy and histologic features | |
| Type of endoscopy | |
| Colonoscopy | 22 (79) |
| Flexible sigmoidoscopy | 6 (21) |
| Endoscopic findings on initial evaluation | |
| Ulceration | 8 (29) |
| Nonulcerative inflammation | 13 (46) |
| Normal | 7 (25) |
| Endoscopic distribution | |
| Extensive | 14 (50) |
| Left colon only | 5 (18) |
| Isolated small bowel | 2 (7) |
| Histological inflammation on initial evaluation | |
| Active features | 28 (100) |
| Chronic features | 14 (50) |
| Microscopic | 10 (36) |
| Median no. of endoscopic procedures (IQR) | 2 (1–7) |
| Diagnostic laboratory studies | |
| Mean duration of laboratory follow-up, months (SD) | 3 (4) |
| Positive fecal lactoferrin at onset of diarrheaa | 23 (100) |
| Positive fecal lactoferrin after vedolizumab therapyb | 11 (79) |
| Mean fecal calprotectin value at onset of diarrhea μg/g (SD)c | 329 (276) |
| Mean fecal calprotectin value at follow-up μg/g (SD)d | 218 (262) |
Abbreviations: IQR, interquartile range; SD, standard deviation.
aLactoferrin was initially measured for 23 patients
bLactoferrin was measured at follow-up for 14 patients
cCalprotectin was initially measured for 19 patients
dCalprotectin was measured at follow-up for 13 patients